Abe T, Tara L A, Lüdecke D K
Department of Neurosurgery, Showa University School of Medicine, Tokyo, Japan.
Neurosurgery. 1999 Jul;45(1):1-10. doi: 10.1097/00006123-199907000-00001.
Pituitary tumors causing gigantism are rare in childhood and adolescence. In a review of 2367 patients with pituitary adenomas who were treated between 1970 and 1997, we found 15 cases (0.63%, 9 male and 6 female patients) of growth hormone-secreting pituitary adenomas in patients who were less than 20 years of age at the time of surgery, and we compared their characteristics with those of adenomas in an adult group.
Patients were grouped according to their ages at the first operation, with five patients (33.3%) in the prepubescent group (0-11 yr), eight (53.3%) in the pubescent group (12-17 yr), and two (13.3%) in the postpubescent group (18-19 yr). All 15 patients exhibited the typical symptoms of growth hormone oversecretion. The incidence of hyperprolactinemia among patients with prepubescent onset was 66.7%. Radiological examinations demonstrated microadenomas in 4 patients (26.7%) and macroadenomas in 11 patients (73.3%). The mean follow-up period was 73.5 months.
Direct transnasal explorations were performed for all patients. Tumor invasion into the cavernous sinus was observed in six patients (40%). Radical tumor resection was performed for four patients (80%) in the prepubescent group, for five patients (62.5%) in the pubescent group, and for neither patient in the postpubescent group. Surgical morbidity was caused by permanent diabetes insipidus in three patients (20%). Rapid growth was postoperatively improved in 80% of the prepubescent age group. The recurrence rate was 13.3% (2 of 15 patients).
Transnasal pituitary surgery was found to be as safe in pediatric patients with gigantism as in adults. Growth hormone-secreting pituitary adenomas in childhood and adolescence were more likely to be invasive or aggressive than were those in adulthood. The clinical biological characteristics for children were different from those for adults.
导致巨人症的垂体肿瘤在儿童和青少年时期较为罕见。在回顾1970年至1997年间接受治疗的2367例垂体腺瘤患者时,我们发现15例(0.63%,9例男性和6例女性患者)生长激素分泌型垂体腺瘤患者在手术时年龄小于20岁,并将他们的特征与成年组腺瘤患者的特征进行了比较。
根据首次手术时的年龄对患者进行分组,青春期前组(0 - 11岁)有5例患者(33.3%),青春期组(12 - 17岁)有8例患者(53.3%),青春期后组(18 - 19岁)有2例患者(13.3%)。所有15例患者均表现出生长激素分泌过多的典型症状。青春期前发病患者中高催乳素血症的发生率为66.7%。影像学检查显示4例患者(26.7%)为微腺瘤,11例患者(73.3%)为大腺瘤。平均随访期为73.5个月。
所有患者均进行了经鼻直接探查。6例患者(40%)观察到肿瘤侵犯海绵窦。青春期前组4例患者(80%)、青春期组5例患者(62.5%)进行了肿瘤根治性切除,青春期后组患者均未进行。3例患者(20%)因永久性尿崩症导致手术并发症。青春期前年龄组80%的患者术后生长过快得到改善。复发率为13.3%(15例患者中有2例)。
经鼻垂体手术在患有巨人症的儿科患者中与在成人中一样安全。儿童和青少年时期生长激素分泌型垂体腺瘤比成人时期的更可能具有侵袭性或攻击性。儿童的临床生物学特征与成人不同。